Insulin Lispro
Complete Research Guide
Open each section for the available evidence. Gaps are stated rather than inferred.
Overview
Insulin Lispro is listed as metabolic / insulin analog.
- •Type 1 Diabetes
- •Type 2 Diabetes
Regulatory status: FDA-Approved Rx.
Structure & Properties
Compound: Insulin Lispro; also known as Humalog, Admelog.
Pharmacologic class: Metabolic / Insulin Analog.
Known delivery routes: Subcutaneous, Intravenous.
Sequence, molecular weight, salt form, and excipient details are formulation-specific and are not listed unless verified by a manufacturer or laboratory COA.
How It Works
Rapid-acting insulin analog — binds insulin receptor to facilitate glucose uptake into muscle and fat; suppresses hepatic glucose output.
- •Rapid postprandial glucose control
- •Flexible meal timing
- •Reduced late-postprandial hypoglycemia vs regular insulin
Human Research
Evidence grade: Clinical RCT (Phase III)
Clinical RCT (Phase III). Multiple Phase III trials.
Laboratory Research
Multiple Phase III trials
Preclinical findings describe biological plausibility, not proven benefit in people. Animal and laboratory doses do not translate directly to human use.
Processing & Interactions
Timing and exposure
Inject within 15 min before or immediately after a meal. Match dose to carbohydrate intake.
Potential interactions and combinations to avoid
- •Pramlintide in the same syringe
- •Alcohol without food — hypoglycemia
Absorption, half-life, metabolism, and clearance can vary by formulation and route. Use prescribing information when an approved product exists.
Safety & Precautions
Known or reported risks
- •Hypoglycemia
- •Hypokalemia
- •Lipodystrophy at injection sites
- •Weight gain
Contraindications
- •Hypoglycemia at time of administration
- •Hypersensitivity to insulin lispro
- •Hypoglycemia or hypoglycemia unawareness
- •Inability to monitor blood glucose reliably or access rapid carbohydrate
- •Concurrent alcohol use, fasting, or prolonged exercise without dose adjustment
- •Hypokalemia or unstable electrolyte status
- •Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- •Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- •Inability to maintain sterile technique or safe sharps disposal
- •Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- •Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- •Children and adolescents with open growth plates (unless under specialist endocrine care)
- •Active or recently treated malignancy without oncology clearance
- •Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Unknown long-term toxicity should be assumed where controlled human data are limited. Seek urgent care for a severe or unexpected reaction.
Administration & Studied Formulations
Reference range: Individualized (units/kg)
Frequency: With meals (rapid-acting)
Cycling: Continuous individualized dosing with meals; no cycling.
Subcutaneous
Within 15 min before meals or immediately after.
Insulin pen (KwikPen) or U-100 syringe; also insulin pumps. Abdomen preferred (fastest absorption), thigh/upper arm alternates. Rotate within site.
IV Infusion
Hospital sliding-scale / DKA protocols.
IV pump, diluted in saline. Clinician-only per protocol.
Dosing information is educational context, not a personal recommendation. Approved products must follow their label and prescriber instructions.
Applications & Related Therapies
Potentially complementary measures
- •Basal insulin regimens; pramlintide with dose reduction
Clinical use should account for diagnosis, approved alternatives, nutrition, activity, sleep, rehabilitation, current medicines, and appropriate monitoring.
Cases, Considerations & Ethics
Decision framework: establish the clinical goal, confirm evidence quality and legal status, screen contraindications and interactions, compare approved alternatives, define monitoring and stopping criteria, and use shared decision-making with a licensed clinician.
Case evidence: individual reports cannot establish safety or effectiveness and should not outweigh controlled trials.
Ethics: informed consent should distinguish established care from experimental use, disclose uncertainty and cost, avoid overstated claims, and never substitute research products for medically necessary care.
Function
Dosing
Recommended Time of Day
Within 15 minutes before, or right after starting, a meal.
See “Timing & Interactions” below for full fasted/fed circumstances, what to avoid combining, and what pairs well.
Administration & Technique
Injection & Application Sites
- Abdomen — 2 in (5 cm) away from the navel, either side. Fastest, most consistent SubQ absorption.
- Outer thigh — Upper outer quadrant, a hand-width below the hip. SubQ pinch at 45°.
- Upper arm / deltoid — Back of the upper arm for SubQ; 2 in below the shoulder bone for IM.
- IV — clinician only — Antecubital vein or central line. Not for home administration.
Diagram is a general illustration, not a medical instruction. Rotate sites every injection, keep 1 in (2.5 cm) between recent sites, and avoid scars, moles, bruises and the navel area.
Cycling
Continuous individualized dosing with meals; no cycling.
Timing & Interactions
- ·Pramlintide in the same syringe
- ·Alcohol without food — hypoglycemia
- ·Basal insulin regimens; pramlintide with dose reduction
Storage & Reconstitution
Reconstitution Calculator
1 mL = 100 units on a standard U-100 insulin syringe. Draw to the nearest 0.5 unit and confirm dosing with a clinician before injection.
Your Notes
Sign in to save personal notes on Insulin Lispro and sync them to Vial Lab.
Benefits
- ·Rapid postprandial glucose control
- ·Flexible meal timing
- ·Reduced late-postprandial hypoglycemia vs regular insulin
Risks
- ·Hypoglycemia
- ·Hypokalemia
- ·Lipodystrophy at injection sites
- ·Weight gain
Contraindications
- ·Hypoglycemia at time of administration
- ·Hypersensitivity to insulin lispro
- ·Hypoglycemia or hypoglycemia unawareness
- ·Inability to monitor blood glucose reliably or access rapid carbohydrate
- ·Concurrent alcohol use, fasting, or prolonged exercise without dose adjustment
- ·Hypokalemia or unstable electrolyte status
- ·Bleeding disorders or anticoagulant therapy without physician guidance (injection-site haematoma)
- ·Active skin infection, cellulitis, or lipohypertrophy at intended injection sites
- ·Inability to maintain sterile technique or safe sharps disposal
- ·Known hypersensitivity or prior reaction to this compound or any excipient/diluent
- ·Pregnancy, attempting conception, or breastfeeding unless prescribed and monitored by a physician
- ·Children and adolescents with open growth plates (unless under specialist endocrine care)
- ·Active or recently treated malignancy without oncology clearance
- ·Use without a confirmed diagnosis, baseline labs, and licensed clinical supervision
Regulatory
FDA-Approved Rx
Veterinary Use (Pets)
No established veterinary protocol for Insulin Lispro. Consult a licensed veterinarian before considering off-label use in any species.
Full veterinary reference →Functional Groups
Cited Works
Tap any study to open the published work.